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ABSTRACT
Methylphenidate is the preferred treatment for

attention-deficit hyperactivity disorder in preschool-aged
children, even though few human studies have assessed the

long-term consequences of early methylphenidate use. In

rats, exposure to methylphenidate during a developmental
period that approximates early childhood increases
morphine-induced antinociception in adulthood. However,

because morphine activates three distinct opioid receptors
it is unknown which receptor(s) is (are) responsible for
this methylphenidate effect. Therefore, the purpose of the

present study was to assess the long-term effects of early
methylphenidate exposure on DAMGO- and U50,488-induced

antinociception, a mu-opioid and kappa-opioid selective
agonist, respectively. Preweanling rats received saline,

2.0 mg/kg methylphenidate, or 5.0 mg/kg methylphenidate

(i.p.) from postnatal day (PD) 11 to PD 20. On PD 60, rats
received DAMGO (0, 1.0, 3.33, or 10.0 pg i.c.v.) or

U50,488 (0, 5.0, 10.0, or 20.0 mg/kg s.c.) prior to
testing in the tail-flick and hot plate tasks.

Methylphenidate pretreatment did not alter responsiveness

to DAMGO. Male rats that received 5.0 mg/kg
methylphenidate pretreatment exhibited significantly

greater tail-flick latencies on the tail-flick task after
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U50,488 administration when compared to saline-pretreated

controls. Female rats that received 5.0 mg/kg

methylphenidate pretreatment demonstrated significantly

shorter basal latencies in the tail-flick task when
compared to saline-pretreated controls. The results

demonstrate that early methylphenidate exposure enhances
the sensitivity of kappa-opioid receptors in male rats and

alters responsiveness to nociceptive stimuli in female

rats. The findings from this study suggest that

methylphenidate treatment during the preschool years may

increase susceptibility to affective and substance abuse
disorders.
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CHAPTER ONE
INTRODUCTION

Attention-deficit hyperactivity disorder (ADHD) is
the most commonly diagnosed psychiatric disorder in

children (American Psychiatric Association, 2000). The

predominant symptoms of ADHD are inattention,
hyperactivity, and impulsivity (American Psychiatric
Association, 2000). Other symptoms include poor self-

esteem, problems regulating emotion, and low threshold for
frustration (American Psychiatric Association, 2000).

Symptoms of ADHD typically manifest in early childhood and
often persist into adulthood (Daley, Jones, Hutchings, &

Thompson, 2008).
The most widely used therapeutic drug to treat ADHD
is methylphenidate. Treatment with methylphenidate reduces
ADHD symptomology in children with ADHD and has been shown

to improve math skills, word comprehension, inappropriate
behavior, and social interaction (Gulley & Northup, 1997;

McGough et al., 2006; Pelham et al., 2002). Duration of
methylphenidate treatment for ADHD typically lasts several

years, and may continue into adolescence and adulthood
(Robin, 1999; Silver, 2000). Methylphenidate is

administered orally and has a therapeutic effect of
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approximately 4 hours with the maximal effect being
achieved 2 hours after consumption (Volkow & Swanson,

2003). Since this duration calls for multiple doses within

a given day, an extended-release preparation, Concerta,
has been developed which has a therapeutic duration of 12

hours (Pelham et al., 2002). Side effects of
methylphenidate include nervousness, insomnia, anorexia,
and dose-related side effects such as increased heart rate
and blood pressure (Schatzberg & Nemeroff, 2006).

Methylphenidate is a psychostimulant that is

structurally similar to amphetamine and exhibits a similar

mechanism of action as cocaine (Volkow & Swanson, 2003) .
Like amphetamine and cocaine, methylphenidate increases

extracellular dopamine concentrations (Volkow & Swanson,

2003). This enhancement of dopamine is believed to
underlie the therapeutic effect of methylphenidate,

presumably by increasing "task-related neuronal firing"

(Volkow & Swanson, 2003) . Because of its similarity to
other drugs of abuse, there is concern that.children who

receive methylphenidate treatment for ADHD may be at an
increased risk of substance abuse later in life

(Schubiner, 2005). However, the majority of literature has
reported a decrease in subsequent drug use in ADHD

stimulant-treated individuals when compared to those who
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were non-treated (Faraone & Wilens, 2003; Schubinerf

.
2005)
Recently, there has been a trend of diagnosing
preschool-aged children (i.e., 3-5 years old) with ADHD

(Zito et al., 2000). Methylphenidate is the most common

stimulant medication to treat children of this age, even
though methylphenidate is only approved by the United
States Food and Drug Administration for use in children

over the age of five (Kollins et al., 2006). This

discrepancy is alarming due to the lack of research
assessing the effectiveness and safety of stimulant use in

this young age group. In the studies available,

methylphenidate appears to improve ADHD symptomology in
3-5 year olds, but has also been shown to have more

adverse side effects and higher rates of discontinuation
when compared to older children (Kollins et al., 2006).
There is also limited research assessing the long-term

consequences of prolonged exposure. This is a concern

because the younger a child, the more plastic the brain,
and therefore the more vulnerable to insult and

chemical-induced alterations (Andersen, 2003). One
particular problem that arises from using stimulant

medications to treat ADHD in preschool-aged children is
the procedures used to diagnose ADHD (Kollins et al.,
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Because parent and teacher ratings of a child's

.
2006)

behavior is used in the diagnostic process (Gopin, Healey,

Castelli, Marks, & Halperin, 2009), and behavior in
preschool children is highly variable (Kollins et al.,

2006) , the probability of misdiagnosing is enhanced.

Because of the paucity of research on the effects of
prolonged methylphenidate exposure in young children, as

well as the ethical and control issues that surround such

research, investigators often employ rodent studies to
assess the long-term consequences of early chronic

methylphenidate. In these studies, rats that received
early methylphenidate have demonstrated increases in

cocaine- and opioid-mediated reward in adulthood, as well
as alterations in affective processes (Balanos, Barrot,

Berton, Wallace-Black, & Nestler, 2003; Brandon,

Marinelli, Baker, & White, 2001; Crawford et al., 2007;

Torres-Reveron & Dow-Edwards, 2005; Valvassori et al.,
2007) .

Most recently, we have demonstrated that early
methylphenidate treatment increases morphine-induced
antinociception (Halladay et al., 2009). This finding
suggests that early methylphenidate exposure causes

permanent alterations in opioid system functioning;

however, it was unclear which opioid receptor(s) is (are)
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responsible for this methylphenidate effect. To further

assess the ability of methylphenidate to alter opioid
system functioning, the present investigation measured the

antinociceptive effects of selective opioid receptor
agonists in rats after early methylphenidate treatment.
In the following chapters, I will discuss the
characteristics and ontogeny of the dopamine and opioid

systems, and the functional interactions between these two

neuronal systems. I will also provide an overview of the
acute, repeated, and long-term effects of methylphenidate

exposure, and the role of the opioids in antinociception.
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CHAPTER TWO
OVERVIEW OF THE DOPAMINE SYSTEM
Dopamine is a neurotransmitter found in the central

nervous system that participates in diverse processes such
as locomotion, cognition, emotion, reward, addiction,
stress, hormone secretion, and the regulation of

homeostasis (Ogawa, 1995; Pierce & Kumaresan, 2006; Smidt,

Smits, & Burbach, 2003). Dopamine is also involved in
various neurological disorders including Parkinson's
disease (Chinta & Anderson, 2004), schizophrenia (Smidt et

al., 2003), Tourette's syndrome (Missale, Nash, Robinson,
Jaber, & Caron, 1998), and ADHD (Le Foil, Gallo, Le Strat,
Lu, & Gorwood, 2009).
Dopamine is synthesized in the presynaptic terminal

of dopaminergic neurons found primarily in the ventral
tegmental area and the substantia nigra of the midbrain

(Meyer & Quenzer, 2005), which together contain 90% of the
total dopamine cell bodies in the brain (Chinta &
Anderson, 2004). The biosynthetic process begins with the
amino acid tyrosine, which is converted into L-DOPA by the

enzyme tyrosine hydroxylase, the rate-limiting step in

dopamine synthesis. Dopa decarboxylase then converts
L-DOPA into dopamine. Along with being an active
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neurochemical of its own, dopamine is also a biosynthetic

intermediate of epinephrine and norepinephrine (Smidt et

al., 2003).
Once released into the synaptic cleft via

calcium-dependent exocytosis, dopamine diffuses throughout
the synapse stimulating pre- and post-synaptic dopamine

receptors. After a short duration of time, dopamine is
cleared from the synaptic cleft by the dopamine

transporter, a transmembrane protein that transports

extracellular dopamine back into the pre-synaptic
terminal. Dopamine molecules that are not recycled by the

dopamine transporter are degraded by the enzyme

catechol-o-methyltransferase (Cooper, Bloom, & Roth,
2003).

The dopamine transporter has a high affinity for
dopamine and mediates the activity of dopamine by
modulating the amount of time it remains in the synaptic
cleft (Cooper et al., 2003). Psychostimulant drugs such as

methylphenidate and cocaine both increase dopamine at the

synapse by blocking the dopamine transporter (Volkow &
Swanson, 2003). When bound by a drug, the transporter is

temporarily inactivated, allowing dopamine to remain in
the synaptic cleft for an extended period of time

resulting in enhanced dopaminergic activity.
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Dopamine cell bodies located in the ventral tegmental
area and substantia nigra send axons in three main fiber
projections: the nigrostriatal pathway, the mesolimbic

pathway, and the mesocortical pathway (Chinta & Anderson,

2005). Collectively, this system is referred to as the

mesencephalic dopaminergic system (Chinta & Anderson,
2005). The nigrostriatal pathway originates in the

substantia nigra and projects to the basal ganglia. The
mesolimbic and mosocortical pathways both originate in the

ventral tegmental area. The mesolimbic pathway projects to
the nucleus accumbens, olfactory tubercle, amygdala and

hippocampus, while the mesocortical pathway projects to
the prefrontal, cingulate, and perirhinal cortex (Pierce &

Kumaresan, 2006).

All dopamine receptors are G-protein coupled,
metabotropic receptors (Cooper et al., 2003). Since the
discovery of dopamine as a neurotransmitter in the 1970's,

five dopamine receptor subtypes have been identified: Dl,
D2, D3, D4 and D5 (Missale et al., 1998). In addition, the
D2 receptor has been further characterized as existing in
two different forms, D2short and D21ong. Both isoforms of
the D2 receptor originate from a similar gene and are

functionally similar (Cooper et al., 2003), with the main

difference being that the D21ong receptor has an
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additional 29 amino acid and show weaker coupling to

particular enzymes when compared to the D2short receptor
(Strange, 1992) . Dopamine receptors are separated into two

categories based on their ability to activate or inhibit

adenylyl cyclase (Missale et al., 1998). Specifically, the
Dl and D5 receptors are referred to as "DI like" and

activate adenylyl cyclase, while the D2short, D21ong, D3,
and D4 receptors are referred to as "D2 like" and inhibit

adenylyl cyclase (Missale et al., 1998). Dl-like receptors
are coupled to one of two G-proteins, Gs or Goif, while the

D2-like receptors are coupled to the G-protein G± (Missale

et al., 1998).
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CHAPTER THREE
THE DEVELOPMENT OF THE DOPAMINE SYSTEM

Embryonic Dopamine Development
The first dopaminergic cells are born by
approximately embryonic day (ED) 12 and begin extending
their axons by ED 13 (Smidt & Burbach, 2007). By ED 14,

dopaminergic axons are detectable in the striatum (van den
Heuvel & Pasterkamp, 2008). Although dopaminergic neurons
project from the substantia nigra to the dorsal striatum
and from the ventral tegmental area to the ventral

striatum in the mature brain, prior to ED 17 these

projections cannot be differentiated (Hu, Cooper,

Crockett, & Zhou, 2004). Following ED 17, dopamine
projections from the substantia nigra and ventral

tegmental area continue to mature and appear to be fully
segregated by the time of birth (Hu et al., 2004). The
prefrontal cortex also receives dopaminergic innervation

during the embryonic period with the first axons being
detectable by ED 15 (van den Heuvel & Pasterkamp, 2008).

These projections, which originate from the midbrain,
first pass through the striatum before entering cortical
areas (van den Heuvel & Pasterkamp, 2008). From ED 15 to

ED 20, midbrain dopamine axons continue to innervate
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various regions of the cortex including the cortical
plate, the somatosensory areas, and the occipital areas

(van den Heuvel & Pasterkamp, 2008). Other areas that
receive dopaminergic innervation include the hippocampus,

amygdala, and hypothalamus; however, much less is known

about these projection sites when compared to striatal and

cortical innervation (van den Heuvel & Pasterkamp, 2008).
Dopaminergic receptors can be detected by the second

week in utero. By ED 14, DI and D2 receptor mRNA are found
in the striatum, olfactory tubercle, frontal cortex, and
cingulate cortex (Schambra et al., 1994). Also by this
embryonic age (i.e., ED 14), DI receptor mRNA is detected

in the thalamus, hypothalamus, spinal cord and retina, and
D2 receptor mRNA is detected in the ventral tegmental area
and substantia nigra (Schambra et al., 1994). Using

immunocytochemistry, tyrosine-hydroxylase, although not a
direct measure of dopamine content, reaches adult levels
by approximately ED 18 (Specht, Pickel, Joh, & Reis,

1981). Dopamine concentrations in the midbrain, as
measured by high performance liquid chromatography, show a
9-fold increase from ED 17 to PD 0 and continue to

increase postnatally (Pares-Herbute, Tapia-Arancibia, &
Astier, 1989). The dopamine transporter is detected in the
midbrain by ED 15 (Perrone-Capano, Tino, & di Porzio,
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1994), and in the striatum and nucleus accumbens by ED 18

(Galineau, Koda, Guilloteau, Vilar, & Cholon, 2004) .

Postnatal Dopamine Development
The dopamine system continues to develop after birth.
Using electron and light microscope immunocytochemistry,

dopaminergic synapses in the striatum peak at PD 7 and
gradually decline until adult levels are reached around PD

21 (Antonopoulos, Dori, Dinopoulos, Chiotelli, &
Parnavelas, 2002). In the nucleus accumbens, dopaminergic

synapses increase until PD 14 and then decrease in number

by PD 21 (Antonopoulos et al., 2002). These results are in
agreement with Voorn, Kalsbeek, Jorritsma-Byham, and
Groenewegen (1988) who demonstrated an increase in

striatal and accumbal dopamine varicosities during the

first and second postnatal week followed by a noticeable

decrease by PD 20 when adult levels are reached.
Dopaminergic innervation of the prefrontal cortex develops
slower than striatal innervation, since adult morphology

is not attained until PD 35 (Kalsbeek, Voorn, Buijs, Pool,

& Uylings, 1988).
Dopamine receptors seem to develop in a similar

manner to dopaminergic projections, because there is a
period of overproduction that occurs after birth followed
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by elimination ("pruning") of over-expressed receptors
(Tarazi & Baldessarini, 2000). This developmental course

is not universally found (Broaddus & Bennett, 1990). For
example, Gelbard, Teicher, Faedda, and Baldessarini (1989)

showed that Dl and D2 receptor densities increase from
birth'to maximal concentrations by PD 40, followed by

pruning to significantly lower levels by PD 120. In

contrast, Broaddus and Bennett (1990) found a 6-fold

increase in D2 binding sites between the first and seventh

postnatal week with no differences in Dl binding sites. In
the prefrontal cortex, Dl receptors undergo a rapid

increase between the first and third postnatal week
followed by a decline between the fourth and sixth
postnatal week (Leslie, Robertson, Cutler, & Bennett,
1991). D2 receptors in the prefrontal cortex demonstrate

similar developmental patterns, because an increase in
receptors occurs between PD 0 and PD 16 followed by a

gradual decline (Chen & Weiss, 1991). The density of
dopamine transporters in the midbrain and striatal regions
are high at birth and slowly decline until adult levels
are reached at PD 28 (Galineau et al., 2004).
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Ontogeny of Dopaminergic Function
Ontogeny of dopamine function can be assessed by

various methods, such as the ability of dopamine receptors
to modulate adenylyl cyclase activity, the measurement of
evoked dopamine release, and the behavioral effects of

various dopaminergic drugs. As previously discussed,
dopamine receptors belong to a super family of G-protein
coupled receptors. Specifically, Dl-like receptors

increase adenylyl cyclase activity, while D2-like
receptors inhibit adenylyl cyclase activity. Within the
striatum, low levels of Dl evoked adenylyl cyclase can be

observed by ED 20 followed by a drastic increase that
peaks at PD 21 followed by a gradual decline to PD 35

where adult levels are reached (Sakagami, Sawamura, &

Kondo, 1995). The D2 receptor develops slower than the Dl
receptor. The ability of the D2 receptor to inhibit

adenylyl cyclase activity is not observable until PD 14
(De Vries et al., 1992). By PD 21, adult levels of
D2-mediated adenylyl cyclase inhibition are reached (De
Vries et al., 1992). •

When considering release characteristics, the amount

of dopamine evoked by the Dl agonist SKF 38393 is

significantly less at PD 10 - PD 11 and PD 20 - PD 21 when
compared to adult rats (Walters & Howard,. 1990). By PD 35,
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SKF 38393-evoked dopamine release is similar to adults

(Walters & Howard, 1990). Young rats exhibit similar
developmental patterns of dopamine release after treatment
with the indirect dopamine agonist methamphetamine. Rats
receiving 4 mg/kg methamphetamine on PD 14 show reduced
dopamine release and higher levels of DOPAC, a metabolite

of dopamine synthesis, when compared to PD 21 rats
(Tsuchida et al., 1996). Another similar ontogenetic

difference is seen with the binding of the DI antagonist

SCH-23390 and the D2 antagonist raclopride. Although Dl
and D2 mRNA is relatively high at birth, the respective

binding of SCH-23390 and raclopride to these receptors

does not reach adult levels until the third postnatal week
(Schambra et al., 1994).
The behavioral effects of dopaminergic drugs also do
not show an adult-like pattern until after the second

postnatal week. At PD 14, the D3 agonist (+)-PD128,907

increases motor activity, whereas in adults (+)-PD128,907

attenuates motor activity (Heijtz, Ogren, & Fuxe, 2000).

By PD 21, adult-like responding is observed (Heijtz et

al., 2000). The behavioral ontogeny of the dopamine system
is also demonstrated by the interaction of dopamine
agonists and antagonists. The locomotor and grooming

behavior induced by the Dl agonist SKF 38393 is attenuated
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by the DI antagonist SCH 23390 in 17 day-old rats, but not

11 day-old rats (McDougall, Arnonld, & Nonneman, 1990).
The functional development of the autoreceptor can be
demonstrated pharmacologically by the D2/D3 agonist
quinpirole (van Hartesveldt, Meyer, & Potter, 1994). In

10, 15, and 20 day-old rats low doses of quinpirole

increase locomotor activity, whereas the same doses of
quinpirole decrease locomotor activity in 30 and 60
day-old rats, suggesting that the autoreceptor develops

relatively late in postnatal life (van Hartesveldt et al.,

1994). Interestingly, apomorphine, a dopamine agonist that
also activates autoreceptors, is able to attenuate

potassium-evoked dopamine in the neostriatum by PD 5 as
measured by in vivo microdialysis (Gazzara & Anderson,

1994). Considering these results together, it appears that
the dopamine autoreceptor is functional early in

development, but it does not induce adult-like effects
until approximately the third postnatal week.
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CHAPTER FOUR

OVERVIEW OF THE OPIOID SYSTEM

The endogenous opioid system is involved in pain
perception, cognitive functioning, affective behaviors,
locomotion, and water consumption (Reisine, 1995) . Drugs
that target the opioid system induce euphoria, analgesia,
sedation, diuresis, miosis, constipation, and respiratory

depression (Pierce & Kumaresan, 2006). Within the opioid
family, there are three distinct opioid ligands:

enkephalin, beta-endorphin, and dynorphin, and three
opioid receptor subtypes: the delta receptor (DOR), mu

receptor (MOR), and kappa receptor (KOR).

Contrary to dopamine, which is synthesized in the

presynaptic terminal, opioids are synthesized on ribosomes
in the soma or dendrites and are transported to the

presynaptic terminal for release (Cooper et al., 2003).
Also unlike dopamine, opioids are derived from inactive
prohormones that undergo proteolytic cleavage to become

neuroactive peptides (Meyer & Quenzer, 2005) .
Proenkephalin, proopiomelanocortin, and prodynorphin are
the prohormones that are cleaved to become enkephalin,

beta-endorphin, and dynorphin, respectively (van Ree et

al., 1999). Similar to dopamine and other
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neurotransmitters, opioids are released from the
presynaptic terminal via calcium-dependent exocytosis

(Cooper et al., 2003). However, inactivation is
accomplished solely through enzymatic degradation, since
the opioids do not have reuptake transporters (Armstrong,

Wynn, & Sandson, 2009). In addition, opioid ligands are
often referred to as "neuromodulators" as opposed to

"neurotransmitters," because opioids often coexist with
other neurotransmitters and modulate the activity of those

neurotransmitters (i.e., "embellishing what the primary

[neuro]transmitter for a neuronal connection seeks to
accomplish")

(Cooper et al., 2001, p. 328).

Among the opioid ligands, dynorphin has a high
affinity for KOR and a low affinity for MOR and DOR,

suggesting that dynorphin is the endogenous ligand for KOR
(Reisine, 1995). Enkephalin is believed to be the

endogenous ligand for DOR and beta-endorphin for MOR
(Narita et al., 2001); however, both ligands share a high

binding affinity for DOR and MOR subtypes, with some
reports showing that enkephalin expresses an equal
affinity for both receptors (Law & Loh, 1999; Van Ree et

al., 1995). Thus, enkephalin or beta-endorphin appear

capable of stimulating either DOR or MOR depending on
localized concentration (Reisine, 1995).
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Opioid receptors are widely dispersed throughout the

central nervous system. Through the use of
autoradiography, the primary localization of these

receptors has been identified. MOR are the most densely
expressed opioid receptor in the brain. The highest

concentrations of MOR are found in the striatum, nucleus
accumbens, dentate gyrus of the hippocampus, regions of
the thalamus, amygdala, pars reticulata of the substantia

nigra, ventral tegmental area, interpeduncular nucleus,

inferior colliculi, raphe nuclei, locus coeruleus, and
layers I and III of the neocortex (Mansour, Khachaturia,

Lewis, Akil, & Watson, 1987; Sharif & Hughes, 1989; Tempel
& Zukin, 1987). DOR are mainly located in the olfactory

bulb, striatum, nucleus accumbens, amygdala, and layers I,

II, V, and VI of the neocortex (Sharif & Hughes, 1989).

KOR primarily exist in the dentate gyrus of the
hippocampus, the nucleus accumbens, striatum, thalamus,
and throughout most layers of the neocortex (Tempel &

Zukin, 1987).

All opioids produce a modulatory effect through the

activation of associated Gi/Go G-proteins. Typically,
activating these G-proteins inhibits neurotransmitter
release at a given synapse by mediating potassium

channels, calcium channels, or adenylyl cyclase activity
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(Grudt & Williams, 1995; Meyer & Quenzar, 2005). Studying
the consequences of opioid-stimulated Gi/G0 proteins has

yielded conflicting results. It has been demonstrated that

opioid-induced Gi/G0 activation modulates calcium channels
on the plasma membrane that results in decreased
intracellular calcium influx and therefore a decrease in

neurotransmitter release (Cooper et al., 2001). For
example, stimulation of KOR and DOR in the striatum
inhibits dopamine and acetylcholine release, respectively

(Mulder, Wardeh, Hogenboom & Frankhuyzen, 1984).
Similarly, activation of MOR in the VTA inhibits GABA
release (Pierce & Kumaresan, 2006). However, other studies

have shown that opioid receptor activation modulates
calcium channels leading to increased calcium influx, thus

resulting in an increase of neurotransmitter release

(Samways & Henderson, 2006). For example, activation of
MOR and DOR increases adenosine release in the spinal cord

(Samways & Henderson, 2006). In terms of these
discrepancies, it is important to understand that opioids
are modulators, and depend on interactions with many

different proteins that collectively produce a response.
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CHAPTER FIVE

THE DEVELOPING OPIOID SYSTEM
Ontogeny of Opioid Peptide Concentrations

Similar to the dopamine system, the endogenous opioid

^system begins to develop during the embryonic period. By
ED 13, beta-endorphin immunoreactivity is detected (Boyon,

Shoemaker, Bloom, Mauss, & Guillemin, 1979). Shortly
after, the presence of enkephalin and dynoprhin is
observed (Boyon et al., 1979). As the rat brain begins to

mature, opioid peptides follow different developmental
patterns. For example, the concentration of beta-endorphin

is greater than enkephalin at ED 16, but drops below

enkephalin levels by the perinatal period (i.e., ED 20 to
PD 5)

(Boyon et al., 1979). Another developmental

difference is observed in the striatum. Although both
endorphin and enkephalin increase from PD 6 to PD 25 in

the medulla, telencephalon, diencephalon, hippocampus, and

amygdala, the concentration of endorphin decreases in the
striatum while enkephalin increases during the same time
span (Boyon et al., 1979). In the hippocampus, dynorphin
can be observed at PD 7, while enkephalin is not detected

until PD 13 (Gall, 1984).
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Opioid peptides show different developmental patterns
depending on brain region. Dynorphin reaches adult levels

in the substantia nigra by PD 7, while adult levels are
not reached until PD 21 in the anterior pituitary (Sei &

Dores, 1990). In the striatum,•adult levels of enkephalin
are reached by PD 21, whereas in the anterior pituitary

the concentration of enkephalin increases linearly until
adulthood (Patey, de la Baume, Gros, & Schwartz, 1980). By

PD 14, beta-endorphin levels in the medulla are

adult-like, whereas beta-endorphin in the anterior
pituitary is at only 21% of adult levels by PD 41 (Alessi
& Khachaturian, 1985; Alessi, Khachaturian, Watson, &

Akil, 1983).
Ontogeny of Opioid Receptor Concentrations

Opioid receptors also differ in their ontogeny. MOR
and KOR can be detected by the second embryonic week in
the striatum, thalamus, hypothalamus, and cortex (Georges,

Normand, Bloch, & Le Moine, 1-998) . DOR develops slower
than MOR and KOR and does not emerge until ED 21, where

they can be detected in the striatum, thalamus,
hypothalamus, and cortex (Georges et al., 1998).

Developmental differences among opioid receptors are also

observed postnatally. KOR is abundantly expressed in the
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ventral tegmental area and substantia nigra during early
postnatal development, whereas DOR are undetectable and

MOR significantly less expressed (Georges et al., 1998).
Within the spinal chord, MOR and KOR binding increases

from PD 0 and peaks at PD 7 followed by a substantial

decline by PD 21 (Rahman, Dashwood, Fitzgerald,

Aynsley-Green, & Dickenson, 1998). The postnatal
development of DOR takes on a much different ontogenetic

route. DOR binding is not observed until PD 14 in the

spinal cord (Rahman et al., 1998). Once DOR are detected,
binding in the spinal chord remains constant through
adulthood (Rahman et al., 1998).

Ontogeny of Opioid Function
Because all three opioid receptor subtypes mediate
analgesia, it serves as a good behavior assay to assess
the ontogeny of opioid function (Zhang & Pasternak, 1981).

At PD 2, rats are relatively insensitive to the analgesic
effects of morphine (ED50 = 56 mg/kg)

(Zhang & Pasternak,

1981). However, by PD 14 the effective dose drops
substantially to 1.4 mg/kg (Zhang & Pasternak, 1981).

Interestingly, in this study there were no reported
differences in respiratory depression between PD 2 and PD

14 pups (Zhang & Pasternak, 1981). In a different
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investigation, the effective dose to induce analgesia by
the MOR-agonist fentanyl was lowest at PD 7 (Laferriere,

Colin-Durand, & Moss, 2005). Higher doses of fentanyl were
required to generate analgesia at PD 14 and in adult rats

(Laferriere et al., 2005).
Opioid-induced behavioral activity also differs

between the young and adult rat. In the adult rat, low
doses of morphine (i.e., 1-2 mg/kg) cause hyperlocomotion,
while suppressing locomotion at PD 5, PD 10, and PD 20
(Iwamoto, 1981; Jackson & Kitchen, 1989). Another major

difference between young and adult rats is observed after
treatment with the KOR agonist 050,488. Opposite to what
is seen in adults, 050,488 increases locomotion in the 5,

10, and 20-day-old rat (Jackson & Kitchen, 1989). Similar
to its emergence during the embryonic period, the

functional ontogeny of DOR appear to lag behind MOR and

KOR, because at PD 20 various doses of the DOR agonist
DPDPE do not produce any behavioral effects (Jackson &
Kitchen, 1989).
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CHAPTER SIX
DOPAMINE-OPIOID INTERACTIONS

The Effect of Dopamine-Enhancing Drugs
on the Opioid System
Although two distinct neuronal systems, activation of
the dopaminergic system affects opioid system functioning.

Repeated exposure to cocaine causes an up-regulation of
MOR in the rostral cingulate cortex, nucleus accumbens,
striatum, and basolateral amygdala (Unterwald, Rubenfeld,
& Kreek, 1994). Increases in KOR densities are also

exhibited after chronic cocaine treatment, primarily in

the rostral cingulate cortex, striatum, caudal olfactory

tubercle, and ventral tegmental area (Unterwald et al.,

1994). Cocaine does not affect DOR (Unterwald et al.,
1994). Dopaminergic stimulation also increases opioid
peptide biosynthesis. Rats given seven days of access to

cocaine via self-administration showed an increase in
dynorphin and enkephalin mRNA in the striatum, and an
increase in dynorphin mRNA in the nucleus accumbens (Hurd,

Brown, Finlay, Fibiger, & Gerfen, 1992). Interestingly,

chronic treatment with the neuroleptic drug haloperidol, a
dopamine antagonist, increases enkephalin concentrations

in the striatum (De Vries, Jonker, Voorn, Mulder, &
Schoffelmeer, 1994) .
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Dopamine-enhancing drugs also alter opioid-mediated

behaviors. During the preweanling period, the D2 agonist
NPA increases the analgesic effect of the KOR agonist

U50,488

(Nazarian, Rodarte-Freeman, & McDougall, 1999). In

addition, ultrasonic vocalizations induced by U50,488 are

attenuated by NPA and cocaine, while U50,488-induced
locomotion is decreased by NPA and the dopamine antagonist

flupenthixol (Nazarian et al., 1999). There have also been

studies investigating the effect of early exposure to
dopamine drugs on opioid-mediated behaviors in the adult

rat. Exposing young rats to daily methylphenidate (i.e.,
PD 11 to PD 20) alters morphine-induced behaviors in adult

rats (Crawford et al., 2007; Halladay et al., 2009).
Specifically, early methylphenidate exposure increased

preference for the morphine-paired chamber in the
conditioned place preference paradigm, and the
antinociceptive effect of morphine in the hot plate task

(Crawford et al., 2007; Halladay et al., 2009). Wiley,
Poveromo, Antapasis, Herrera, and Bolanos (2009) showed

alterations in KOR functioning in rats exposed to
methylphenidate during preadolescence (i.e., PD 20 to

PD 35). Specifically, methylphenidate-treated rats showed
an increase in anxiety- and stress-like behaviors, as

measured by the elevated plus maze and forced swim tests
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'(Wiley et al., 2009). This enhanced effect of
methylphenidate in the elevated plus maze was attenuated

by the KOR-antagonist nor-binaltorphimine (Wiley et al.,
2009). In addition, the enhanced effect of methylphenidate
in the forced swim test was intensified by U50,488 (Wiley

et al., 2009) .
Effects of Opioid-Enhancing Drugs
on the Dopamine System

Opioid-like drugs have also been shown to alter
dopamine system functioning. In the striatum, chronic

morphine decreases D2 receptor mRNA, increases D3 receptor
mRNA, and does not affect DI receptor mRNA (Georges,

Stinus, Block, & Le Moine, 1999; Spangler, Goddard, Avena,
Hoebel, & Leibowitz, 2003). Administration of opioid-like

drugs also affects dopamine levels. Specifically, MOR and
DOR agonists increase extracellular dopamine, whereas MOR
and DOR antagonists decrease dopamine (Herz, 1998).

Interestingly, KOR appear to have an opposite effect on

dopaminergic activation because KOR agonists decrease,
whereas KOR antagonists increase, dopamine concentrations
(Herz, 1998).

Another way the functional interactions between the
opioid and dopamine systems can be demonstrated is by

assessing the opioid-mediated inhibition of
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dopamine-stimulated adenylyl cyclase activity. Activating
striatal MOR or DOR receptors decreases Dl-evoked cyclic
AMP production, which is blocked by naloxone and the

DOR-antagonist ICI 174864, respectively (Schoffelmeer,
Hogenboom, & Mulder, 1987). The ability of opioid

receptors to attenuate dopamine-activated adenylyl cyclase
is reduced after treatment with haloperidol (De Vries et

al., 1994). This effect is mediated primarily by DOR,
because the ability of the selective delta agonist DPDPE

to stimulate DOR was diminished after haloperidol
treatment, while the activation of MOR by the selective mu

agonist DAMGO was unaffected (De Vries et al., 1994). In
addition, activation of the opioid system has profound

effects on dopamine-mediated behaviors. Repeated

administration of the KOR agonist U69593 attenuates the
locomotor activity induced by cocaine and the D2 agonist
quinpirole, and blocks cocaine-induced behavioral
sensitization (Acri, Thompson, & Shippenberg, 2001;

Heidbreder & Shippenberg, 1994).
The ability of the opioid system to modulate the

dopamine system is also observable during the embryonic

period. As early as ED 17, Dl-stimulated adenylyl cyclase
is inhibited by DAMGO and U50,488

(De Vries, Hogenboom,

Mulder, & Schoffelmeer, 1990). Interestingly, the ability
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of DOR to modulate adenylyl cyclase is not observed until
PD 14 (De Vries et al., 1990).
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CHAPTER SEVEN
METHYLPHENIDATE

Methylphenidate Overview

Methylphenidate is a psychostimulant drug commonly
used for the treatment of ADHD. Similar to other

psychostimulants (e.g., cocaine and amphetamine),
methylphenidate is an indirect agonist that increases
dopamine and norepinephrine concentrations in the synaptic

cleft by binding to re-uptake transporters (Markowitz,
DeVane, Pestreich, Patrick, & Muniz, 2006). Although the

therapeutic effect is believed to be due from the
enhancement of dopamine, methylphenidate binds with

greatest affinity to the norepinephrine transporter
(Markowitz et al., 2006). Methylphenidate has a relatively
long half-life compared to other psychostimulants. At a 10

mg/kg dose, the therapeutic effect of methylphenidate

lasts approximately four hours, with the maximal effect
being achieved two hours after consumption (Volkow &
Swanson, 2003). Methylphenidate is metabolized into

ritalinic acid by deesterification and excreted through

urine within 48 hours (Faraj et al., 1974).
Various properties distinguish methylphenidate from
other psychostimulants. Although having a similar affinity
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for the dopamine transporter as cocaine, methylphenidate
has a much slower clearance rate than cocaine, a quality

that enhances methylphenidate's appeal as a medication and

decreases its abuse potential (Volkow et al., 1995). In

addition, cocaine increases serotonin concentrations by
binding to the serotonin transporter, whereas

methylphenidate exhibits no affinity for the serotonin

transporter (Ravna, Sylte, & Dahl, 2003). Methylphenidate
also differs from amphetamine, another psychostimulant
commonly used for the treatment of ADHD. Unlike

methylphenidate, which acts strictly at re-uptake sites,
amphetamine enters the presynaptic neuron, reversing the
direction of the re-uptake transporters and inhibiting

monoamine oxidase, an enzyme that catabolizes
catecholamines not contained in presynaptic vesicles

(Heal, Cheetham, & Smith, 2009) .
Effects of Acute Methylphenidate Administration
Acute administration of methylphenidate to children
and adults, with and without ADHD, is reported to increase

attention, while decreasing activity and impulsivity
(Solanto, 1998). When given orally, methylphenidate does
not appear to be reinforcing (Volkow & Swanson, 2003).

However, when using different routes of administration
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(e.g., injecting, sniffing, or smoking), methylphenidate

is more rapidly absorbed into the blood stream and may
result in a "high" similar to cocaine (Volkow & Swanson,

2003). Physiological side effects of acutely administered

methylphenidate include transient increases in blood
pressure and heart rate (Rapport & Moffitt, 2002).

In rats, low doses of acutely administered
methylphenidate improve working memory, enhance inhibitory
control, and increase attention (Arnsten & Dudley, 2005;

Berridge et al., 2006). In addition, methylphenidate,
similar to other psychostimulants, increases locomotor
activity and, at high doses, induces stereotypic behaviors

(Askenasy, Taber, Yang, & Dafny, 2007). Similar to humans,

oral methylphenidate is not as reinforcing to rats as
alternate routes. Compared to intraperitoneal (i.p.)
administration, oral methylphenidate is weaker at

reinstating methylphenidate-seeking behavior (Botly,

Burton, Rizos, & Fletcher, 2008). In addition, 0.75 to
3.0 mg/kg oral methylphenidate has no effect on dopamine

concentrations in the nucleus accumbens, a brain area

associated with drug reinforcement (Kuczenski & Segal,
2002).
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Effects of Repeated Methylphenidate
Administration

Tolerance is reported to develop after prolonged
exposure to methylphenidate in children with ADHD, which

is typically ameliorated by increasing the dose of
methylphenidate or switching to an alternate stimulant
medication (Ross, Fischhoff, & Davenport, 2002).
Regardless, treating ADHD with chronic methylphenidate has

been shown to improve various cognitive deficits. For
example, treating 7-15 year old male participants for 12

months with methylphenidate increases memory recognition
and executive demand performance when compared to placebo

controls (Coghill, Rhodes, & Matthews, 2007). Other
deficits in children with ADHD appear to be unaltered by
repeated methylphenidate treatment, because treating 7-12
year old children with methylphenidate for seven weeks

caused no improvement in response inhibition (van der
Meere, Gunning, & Stemerdink, 1999).

In animals, repeated administration of
methylphenidate enhances drug-induced locomotion, a
phenomenon known as behavioral sensitization (Yang, Swann,
& Dafny, 2007). This raises a concern regarding chronic
methylphenidate, because behavioral sensitization is

believed to model certain aspects of drug addiction
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(Askenasy et al., 2009). The reinforcing properties of
methylphenidate can be demonstrated in the

self-administration procedure, a paradigm where the rat
controls the amount of drug consumption by pressing a

lever for intravenous drug infusions (Brandon, Marinelli,
Baker, & White, 2001; Collins, Weeks, Cooper, Good, &
Russell, 1984). Repeated exposure to methylphenidate also

supports place preference conditioning (Sellings, McQuade,

& Clarke, 2006). In this paradigm, an animal is repeatedly

administered methylphenidate in a specific context and
saline in an alternate, distinct context. When given free
choice between the two contexts, the rat's "preference"
for the drug is determined by the amount of time spent in
the methylphenidate-paired context.

Methylphenidate also affects cognition. Rats

receiving 0.3 mg/kg methylphenidate from PD 22 to PD 29

showed increased acquisition in the radial arm maze
compared to vehicle controls (Dow-Edwards, Weedon, &
Hellmann, 2008). However, continuing methylphenidate

treatment until early adulthood (i.e., PD 59) resulted in
no differences between drug- and saline-treated animals. A

modest increase in behavioral flexibility has also been
reported after chronic methylphenidate treatment (Seu &

Jentsch, 2009).
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Long-Term Effects of Chronic Methylphenidate
A concern with using methylphenidate to treat ADHD is
the long-term consequences of prolonged stimulant

exposure. Since the pharmacodynamics of methylphenidate is

similar to other drugs of abuse, it has been postulated
that prolonged exposure to methylphenidate may increase
the susceptibility of substance abuse later in life

(Schubiner, 2005). Although studies are limited, the
extant literature is controversial. Some studies have
reported that stimulant treatment of ADHD increases the

risk of later drug use (Lambert & Hartshough, 1998),
whereas others have shown no difference in subsequent drug
use based on stimulant-treatment history (Biederman et

al., 2008). Interestingly, the majority of literature has
indicated that stimulant-treated individuals show a

decrease in subsequent drug use when compared to a

non-treated sample (Wilens, Faraone, & Bierderman, 2003).
In a meta-analysis that combined six different
longitudinal studies, children who received ADHD treatment
(e.g., methylphenidate or amphetamine) showed a 50%

decreased risk of developing substance abuse later in life
verses those who were untreated (Wilens et al., 2003).
Currently, there is limited research investigating the
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cognitive functioning of adults that received
methylphenidate treatment for ADHD as children.

Compared to the human literature, there has been much
more research in the animal literature investigating the
long-term effects of prolonged methylphenidate. Rats

treated twice-daily from PD 20 to PD 35 with

methylphenidate demonstrate altered emotional responses in

adulthood (Bolanos, Barrot, Berton, Wallace-Black, &
Nestler, 2003). Specifically, methylphenidate-treated
adults showed reduced responses to sucrose,

novelty-induced activity, and sexual behavior when
compared to control animals (Bolanos et al., 2003). In

addition, methylphenidate-treated rats showed a heightened
level of sensitivity to stressful situations and exhibited

increased levels of plasma corticosterone (Bolanos et al.,
2003).

Alterations in drug reward have also been shown in

rats exposed to methylphenidate during a young age. Rats
given methylphenidate from PD 35 to PD 42 demonstrated a

significantly greater number of cocaine infusions in the

self-administration paradigm when compared to vehicle

controls (Brandon et al., 2001). In contrast, rats
pretreated with methylphenidate as adolescents (i.e., PD

20 to PD 35) showed a reduced response to cocaine reward
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in the conditioned place preference paradigm (Carlezon,

Mague, & Andersen, 2003) . The age of the rat during
methylphenidate exposure (i.e., adolescents vs
preadolescents) and differences in testing paradigms

(i.e., self-administration vs conditioned place

preference) may account for the different pattern of
results reported in the two studies. Early treatment with

methylphenidate also produces cross-sensitization to

cocaine when tested in adulthood. Rats receiving daily
treatments of 10 or 20 mg/kg methylphenidate from PD 21 to

PD 26 exhibited an enhanced response to cocaine when
tested as adults (Torres-Reveron & Dow-Edwards, 2005).

Early methylphenidate exposure affects other

neurotransmitter systems, in particular the opioid system.
Treating rats with 5 mg/kg methylphenidate from PD 11 to
PD 20 produced an enhancement of morphine-induced

conditioned place-preference (Crawford et al., 2007).
Methylphenidate pretreatment also increases the
reinforcing value of sucrose (Crawford et al., 2007), a

process mediated by the opioid system (Papaleo, Kieffer,
Tabarin, & Contarino, 2007). Specifically, animals that
received methylphenidate pretreatment (i.e., 2 and 5

mg/kg) exhibited higher break point levels in
sucrose-reinforced lever-pressing compared to control
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animals (Crawford et al., 2007). Halladay et al.

(2009)

showed an increase in morphine-induced antinociception in
rats pretreated from PD 11 to 20 with 5 mg/kg
methylphenidate. In addition, methylphenidate pretreatment
enhanced morphine-induced locomotor activity at moderate

doses (i.e., 2.5 and 5 mg/kg), and decreased locomotor
activity at high doses (10 mg/kg) compared to vehicle

controls (Halladay et al., 2009).
In addition to behavioral studies, investigations
also show neurochemical alterations after chronic

methylphenidate treatment. For example, rats pretreated
with 2 mg/kg methylphenidate from PD 25 to PD 39 showed a

significant reduction of dopamine re-uptake transporter

sites in the striatum, but not the midbrain, at PD 70
(Moll, Hause, Ruther, Rothenberger , & Huether, 2001).

Serotonin and norepinephrine transporter densities were

unaffected by early methylphenidate exposure (Moll et al.,
2001). In addition, 2 mg/kg methylphenidate treatment from
PD 20 to PD 35 reduced the survival rate of newly born
hippocampal cells in adulthood (Lagace, Yee, Bolanos, &
Elsch, 2006). Other studies show short-term

neuroadaptations after chronic methylphenidate treatment,
but no long-term neuronal alterations. Using

immunocytochemistry, rats treated with 5 mg/kg
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methylphenidate twice daily from PD 7 to PD 35 exhibited

an increase in tyrosine hydroxylase immunoreactivity in
the medial prefrontal cortex and a decrease in the medial

striatum at PD 35, as well as reduced norepinephrine

transporter densities in the medial prefrontal cortex and
hippocampal dentate gyrus (Gray et al., 2007). At PD 135

there was only a trend for decreased tyrosine hyroxylase

immunoreactivity in the medial prefrontal cortex (Gray et
al., 2007).
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CHAPTER EIGHT

ANTINOCICEPTION
Overview
The sensation of pain is mediated by nociceptive

neurons. The cell bodies of nociceptive neurons are
located in the dorsal horn of the spinal cord (Stamford,

1995). The firing of nociceptive neurons results in the

sensation of pain and, conversely, the inhibition of these
neurons attenuates the perception of pain (i.e.,

analgesia)

(Stamford, 1995). In addition to the spinal

cord, supraspinal brain regions are also involved in the

perception of pain, including the cerebral cortex,
amygdala, thalamus, nucleus accumbens, and various nuclei

of the brainstem (e.g., periaqueductal grey (PAG), raphe
nuclei, medulla, and the locus coeruleus)

(Bodnar, 2000;

Gear & Levine, 1995; Stamford, 1995). Neurotransmitters
that are involved in pain include norepinephrine,

serotonin, GABA, acetylcholine, substance P, and the

opioids (Stamford, 1995; Todd, 2002).
Antinociception and the Opioid System
The involvement of the opioid system in pain

processes has been extensively investigated (Basbaum &
Fields, 1984; Bodnar, 2000; Fanselow, Calcagnetti, &
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Helmstetter, 1989; Stamford, 1995). The activation of the
opioid system results in antinociception, and therefore

drugs that increase opioid activation are used for the

treatment of pain (Stamford, 1995). Of all the

opioid-enhancing drugs, morphine is the most popular agent
used for analgesia (Tortorici, Robbins, & Morgan, 1999).

Systemic injection of morphine produces antinociception as
measured by the shock-titration, tail-flick, and hot plate
tasks (Gades, Danneman, Wixson, & Tolley, 2000; Markowitz,

Jacobson, Bain, & Kornetsky, 197 6) . In addition to

morphine, which is primarily a MOR-acting drug, selective

agonists for DOR and KOR receptors also participate in the
modulation of pain. Subcutaneous injection of the KOR

agonist U50,488 and U69,593 induces analgesia, which is
demonstrated by increased latencies in the tail-flick task

(Millan, 1989). The DOR agonist deltorphin also produces
antinociception as measured by the formalin test (Chiba,
Murase, Ambo, & Sasaki, 1996).
In order to localize regions of opioid actions within
the brain and spinal cord, microinjection procedures are

often used. Microinjecting morphine into the dorsal horn

of the spinal cord induces analgesia as measured by the

tail-flick and hot plate tasks (Kline & Wiley, 2008) .
Morphine can also produce antinociception when
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microinjected into supraspinal brain regions including the
PAG and reticular formation (Yaksh & Rudy, 1978).

Forebrain regions, such as the amygdala, also play a role,
because amygdaloid lesions attenuate morphine-induced

analgesia (Manning & Mayer, 1995). Similar to morphine,
microinjecting DOR- and KOR-agonists into the spinal cord

inhibits nociceptive neurons and produces analgesia

(Przewlocki, Stala, Greczek, Shearman, Przewlocka, & Herz,

1983). Antinociception also occurs when selective agonists
are microinjected supraspinally . Specifically,

administration of the MOR agonist DAMGO and the DOR

agonist deltorphin into the PAG and rostral ventral
medulla elicits analgesia (Rossi, Pasternak, & Bodnar,

1994). MOR located within the nucleus accumbens also
participate in analgesia, since microinjecting naloxone
into this brain region attenuates DAMGO-induced analgesia

(Gear & Levine, 1995). Supraspinal KOR are also capable of
inducing antinociception, but in some circumstances
attenuates antinociception. For example, microinjecting
the KOR-agonist U50,488 into the dorsal posterior

mesencephalic tegmentum induces analgesia (Hamann &

Martin, 1994); however, administering the KOR-agonist

U69,593 into the rostral ventromedial medulla attenuates
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the antinociception produced by microinjecting DAMGO in

the PAG (Pan, Tershner, & Fields, 1997).

Paradigms for Measuring Antinociception
The analgesic properties of compounds can be measured
in a variety of paradigms. In the rodent literature, there

are generally three types of pain that are assessed:

neuropathic, tonic, and acute pain. Neuropathic pain, or
persistent pain, is typically induced by transectioning or
constricting nerve fibers involved in pain sensation

(Sotgiu, Valente, Starchi, Caramenti, & Biella, 2009). For
example, lesioning or chronically constricting the sciatic
nerve causes continuous pain including hyperalgesia, and

exaggerated responses to non-noxious (i.e., allodynia) and

noxious stimuli that can last for weeks (Sotgiu et al.,
2009). In animal models of neuropathic pain, opioids

mediate antinociception, primarily by activation of MOR
(Wang, Zhao, Huang, Tang, & Yuan, 2008; Zhao, Wang, Jia, &

Tang, 2006).
Tonic pain is usually assessed in one of two types of
procedures: the formalin test or the writhing test. In the

formalin test, a 0.5 to 15% formaldehyde solution (i.e.,
"formalin") is injected into the forepaw or upper lip of
the rat (Le Bars et al., 2001). After formalin
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administration, the behavior of the rat can be assessed on

a number of different scales (i.e., locomotor activity,
twitching, or paw-licking/biting)

(Le Bars et al., 2001).

Interestingly, the formalin test produces "biphasic

behavioral activation," an initial phase that lasts
approximately three minutes followed by a period of low
activity, and a second phase of increased activity between
the 20th and 30th minute after formalin administration (Le

Bars et al., 2001). Opioids induce antinociception in both

phases of the formalin test (Le Bars et al., 2001). In the
writhing test, irritant agents are injected i.p. thus

causing nociception, which is displayed primarily by

abdominal contractions (Le Bars et al., 2001).
Antinociception in the writhing test is not considered to

be a specific measure of analgesia, because non-analgesic

compounds also reduce the number of abdominal contractions
(Le Bars et al., 2001).

Acute pain in animal models is administered by a
short duration of thermal or mechanical stimulation. In
these paradigms, the analgesic properties of compounds are

typically assessed by comparing the time to escape the
nociceptive stimuli (Le Bars et al., 2001). The tail-flick
and hot plate procedures are commonly used acute pain

paradigms, because both procedures are easy to quantify,
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relatively harmless to the subjects, and are responsive to
opioid receptor'agonists.

In the tail-flick task, the analgesic properties of a
compound can be assessed by measuring tail-withdrawal

latency after immersion in heated water or after applying

radiant heat (Le Bars et al., 2001). MOR, DOR, and KOR
agonists increase latencies in the tail-flick task (Tseng,

Henneberry, & Collins, 1995; Tseng, Tsai, Collins, &
Portoghese, 1995). The tail-flick task is primarily a

measure of spinal-mediated analgesia, because

antinociception can be induced by opioids after
transcectioning or deactivating, via cold-blocking, the
dorsal part of the spinal cord (Le Bars et al., 2001).
This is not to say that supraspinal mechanisms are not

involved, because morphine is the most effective at
inducing analgesia in the tail-flick task in intact rats

(Sinclair, Main, & Lo, 1988).

In the hot plate task, animals are placed in a
chamber with a heated metallic floor and the latency to
lick the paw or jump is recorded (Le Bars et al., 2001).

Analgesia in the hot plate task is mediated by all three

opioid receptors, because intracerebroventricular
administration of MOR, DOR, or KOR selective agonists

increases paw-lick, latencies (Porreca, Mosberg, Hurst,
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Hruby, & Burks, 1984). Unlike the tail-flick procedure,
the hot plate task is considered to be a measure of

supraspinal-mediated nociception (Flores, El Banoua,
Galan-Rodriguez, & Fernandez-Espejo, 2004; Le Bars et al.,
2001).
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CHAPTER NINE

THESIS STATEMENT
The increased use of methylphenidate in young
children has led to concerns about the long-term
consequence of early exposure to this compound. Although

limited longitudinal human data exist, recent ontogenetic
studies in rodents have shown that early methylphenidate
treatment alters affective behavior and the response to

drugs of abuse (Bolanos et al., 2003; Brandon et al.,
2003; Crawford et al., 2007). The specific neuronal

alterations caused by early methylphenidate exposure

remain unknown; however, it is possible that changes in
opioid receptor functioning underlie methylphenidate-

induced behavioral alterations. This suggestion is based
on three previous findings:

(1) repeated treatment with

psychostimulants (e.g., cocaine) increases the density of

MOR and KOR receptors in adult rats (Unterwald et al.,
1994);

(2) the KOR antagonist, nor-binaltorphimine, blocks

changes in affective behavior and drug responsiveness
caused by early methylphenidate exposure (Wiley et al.,

2009); and (3) early exposure to methylphenidate enhances
the antinociceptive effects of morphine (Halladay et al.,

2009). Thus, the goal of the proposed thesis is to further
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characterize the role of MOR and KOR in

methylphenidate-mediated behavioral changes.

To this end, antinociception was used to assess
opioid receptor functioning. While opioid receptors
mediate a number of behaviors, antinociception was chosen
because it is easily quantified, sensitive to
dose-response relationships, and is mediated by all opioid

receptor subtypes. Two antinociception experiments are
proposed for my thesis. In Experiment 1, the

antinociceptive effect of the MOR-agonist DAMGO was
assessed in adult rats that had been exposed to

methylphenidate from PD 11 to PD 20. In Experiment 2, the
antinociceptive effect of the KOR-agonist U50,488 was

assessed in adult rats after exposure to methylphenidate

from PD 11 to PD 20. Because investigations often show
gender differences in antinociception after administration

of opioid agonists (Barrett et al., 2002; Rest, Sarton, &

Dahan, 2000; Lomas, Barrett, Terner, Lysle, & Picker,
2007),-sex was included as an independent variable. For

both experiments, antinociception was measured using the
tail-flick and hot plate tasks. If methylphenidate did not
modulate DAMGO- or U50,488-induced antinociception,

Experiment 3 would be conducted-. In this experiment, the

same methods as in Experiment 1 and 2 would be used, but

48

antinociception would be assessed after treatment with the
DOR-agonist DPDPE.
Based on previous findings that MOR and KOR receptor

densities are increased by repeated psychostimulants and
our previous work with morphine, it was predicted that

early methylphenidate treatment would enhance the
antinociceptive effects of both DAMGO and U50,488.

CHAPTER TEN
METHODS

Subj ects
A total of 314 rats (n - 5-7 per group) of

Sprague-Dawley descent (Charles River Laboratories,
Hollister, CA), born and raised at California State

University, San Bernardino (CSUSB), were used. Litters
were culled to 10 pups on PD 3 and housed with the dam

until PD 25. After weaning, rats were housed (3-5 rats per
cage) with same-sex littermates. The colony room was

maintained at 22-24° C and kept under a 12-hr light/dark

cycle. All animals were treated according to the "Guide
for the Care and Use of Mammals in Neuroscience and

Behavioral Research" (National Research Council, 2003)
under a research protocol approved by the Institutional

Animal Care and Use Committee of CSUSB.
Apparatus

A tail-flick apparatus and hot plate analgesia meter

(IITC Life Science Inc, Woodland Hills, CA) were used to
assess antinociception. An adjustable laser beam was used

to apply radiant heat in the tail-flick task. The hot
plate was heated and maintained at 52.0°C (+ 0.1°C).
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Drugs
Methylphenidate hydrochloride,

d-Ala2,NMePhe4,Gly-ol5]-enkephalin (DAMGO),

[D-Pen2,

D-Pen5]-enkephalin (DPDPE), and U50,488 was purchased from

Sigma-Aldrich (St. Louis, MO). Methylphenidate was
dissolved in saline and injected i.p. at a volume of 5

ml/kg. DAMGO and DPDPE were dissolved in saline and
microinjected intracerebroventricularly (i.c.v.) at a rate

of 1 |xl/min. Because pilot trials of 050,488 (600 jig)
given i.c.v. failed to elicit significant antinociception,

050,488 was dissolved in saline and injected
subcutaneously (s.c.) at a volume of 1 ml/kg.
Methylphenidate Pretreatment
Rats received 0, 2, or 5 mg/kg methylphenidate once

daily from PD 11 to PD 20. This injection period was

chosen because this age span approximates early childhood
in humans (Andersen, 2003, 2005; Andersen & Navalta,

2004).
Intracerebroventricular Cannulation

On PD 54, rats in the DAMGO experiment were
anesthetized with 2.5%-5% isoflurane mixed with oxygen.
Rats were placed in a standard Kopf stereotaxic apparatus
and administered topical lidocaine solution (1%) before
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incising the scalp to reveal the skull. Two anchor screws
were inserted into the skull prior to cannulation. A

single stainless steel guide cannula (22 gauge; Plastics
One, Roanoke, VA) was inserted into the right ventricle

(A/P -0.8, L -1.5, D/V -3.7; Paxinos & Watson, 1986). Once
in position, the cannula was fixed with dental cement and

a dummy guide inserted to prevent clogging. Following

surgery, animals were administered ketoprofen (2 mg/ml)

and allowed five days to recover before behavioral testing

began.
Experiment 1: DAMGO Microinjections

Habituation to the tail-flick and hot plate procedure
occurred on PD 58 and PD 59. For the tail-flick task, each
rat was placed on the tail-flick apparatus for 1 min (no

heat was applied) and on the unheated hot plate for 2 min.

Baseline data for the tail-flick task was collected on PD
60 by holding each rat in position so the laser beam
heated the tail (approximately 1 inch distal from the base

of the tail). Latency until tail-flick was measured.

Immediately after the tail-flick, the rat was removed and
placed on the heated hot plate (52.0°C, ± 0.1°C). Latency

to lick the rear paw or attempt to jump out of the chamber
was measured. This procedure was repeated three times,
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with a 10-min interval between each trial. In all
inter-trial intervals, rats were kept in a holding room
that was separate form the testing room. After these

baseline trials, rats were injected with DAMGO (1.0, 3.33,

or 10.0.p,g i.c.v.) or saline (i.c.v.). After receiving

drug treatment, animals were returned to the holding room
for 20 min. Rats were then tested three additional times

in the tail-flick and hot plate tasks with a 10 min

interval between each trial. To avoid tissue damage, rats
were removed from the tail-flick apparatus after 15 s or

hotplate after 30 s if no response was made. At the
completion of behavioral testing, rats were sacrificed and

cannula placement verified by thionin staining.
Experiment 2: 050,488 Systemic Injections
In Experiment 2, separate groups of rats were

habituated as described in Experiment 1. However, because
an s.c. injection takes longer than an i.c.v. injection to

achieve maximal effect, 20 minutes separated each baseline
and testing trial. After baseline trials, rats were

injected with U50,488 (5.0, 10.0, or 20.0 mg/kg s.c.) or

saline (s.c.). After receiving drug treatment, animals
were returned to the holding room for 20 min. Rats were
then tested three additional times in the tail-flick and
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hot plate tasks with a 20 min interval between each trial.

To avoid tissue damage, rats were removed from the

tail-flick apparatus after 15 s or hotplate after 30 s if
no response was made.

Experiment 3: DPDPE Microinjections
If Experiment 3 were to be conducted, separate groups

of rats would be habituated and baseline data collected as
described above. After baseline trials, rats would be
injected with DPDPE (0.2, 2.0, or 20.0 pg i.c.v.) or
saline (i.c.v.) and returned to their home cage for 20

min. At the completion of behavioral testing, rats would
be sacrificed and cannula placement verified by thionin

staining.
Design and Data Analysis
Analgesic response was measured as latency to tail
flick in the tail-flick task and latency to lick the rear
paw or jump in the hot plate task. Baseline latencies (no
drug) were analyzed by two-way ANOVAs (pre-exposure dose x

sex). Separate 3x2x4 (pre-exposure dose x sex x
testing dose) repeated measures ANOVAs were used to

analyze testing data. Time was not included in the
analysis, because there were no relevant time interactions
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in the test data. Data for Experiment 1 and 2 were

analyzed by separate ANOVAs. Significant higher-order

interactions were further analyzed using one-way ANOVAs.

Post hoc analyses of antinociception data were made using
Tukey tests (p < 0.05). Only rats with correct cannula

placements were used in the statistical analyses for
Experiment 1.

Effect sizes were calculated using eta-squared (q2) .

r|2 estimates the size of shared variance between two or

more variables and is commonly used in ANOVA designs
(Ferguson, 2009) . In determining the strength of T[2,

estimates of 0.04 constituted a small effect, estimates of

0.25 a moderate effect, and estimates of 0.64 a strong
effect (Ferguson, 2009).
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CHAPTER ELEVEN

RESULTS

Experiment 1: DAMGO Microinjections
Tail-Flick
Less than 5% of rats had incorrect cannula placements
(data not shown). These rats were excluded from any

subsequent analyses. Basal responsiveness on the

tail-flick task differed significantly by sex, because

male rats had significantly greater baseline latencies
when compared to female rats (see Figure 1; sex main

effect, F (1, 156) = 9.444, p < 0.005, T]2 = 0.057).
Methylphenidate pretreatment did not alter baseline
responding on the tail-flick task. DAMGO administration
greatly increased tail-flick latencies in both male and

female rats (see Figure 2). Specifically, rats given any
of the three doses of DAMGO (1.0, 3.33, or 10.0 pg) showed

greater tail-flick latencies when compared to rats

receiving saline. In addition, rats receiving the greatest
dose of DAMGO (10.0 pg) had longer tail-flick latencies

when compared to rats that received the lowest dose of

DAMGO (1.0 pg)

[F (3, 138) = 125.655, p < 0.001, Tukey

tests, p < 0.05, T|2 = 0.747]. Neither sex nor
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methylphenidate pretreatment altered the tail-flick

latencies of rats given DAMGO.

Baseline Tail Flick

Pretreatment Drug (mg/kg)
Figure 1. Mean (±SE) Baseline Tail-Flick Latency of Male
and Female Rats (N = 156) Pretreated with Saline,

2.0 mg/kg Methylphenidate, or 5.0 mg/kg Methylphenidate

from PD 11 to PD 20. Data in this Figure are Collapsed
across Baseline Trials. aSignificantly Different from Male

Rats.
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Tail Flick

DAMGO Dose (gg)

Figure 2. Mean (±SE) Tail-Flick Latency of DAMGO (0, 1.0,

3.33, or 10.0 pig i.c.v.) Treated Male and Female Rats
(N = 156). Rats were Pretreated with Saline or

Methylphenidate (2.0 or 5.0 mg/kg) from PD 11 to PD 20 and
Tested with DAMGO on PD 60. aSignificantly Different from

Saline-Treated Rats. bSignificantly Different from Rats
Treated with 1.0 |xg DAMGO.
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Hot Plate

Basal responding on the hot plate was not altered by

either sex or methylphenidate pretreatment (see Figure 3).

Similar to the response on the tail-flick task, rats
receiving DAMGO exhibited significantly greater latencies

when compared to rats receiving saline (see Figure 4). The

increase in paw-lick latencies on the hot plate task was
dose-dependent, because greater doses of DAMGO elicited

greater latencies than lower doses [F (3, 138) = 73.317,
p < 0.001, Tukey tests, p < 0.05, r|2 = 0.614). Unlike the

tail-flick task, however, methylphenidate pretreatment
altered paw lick latencies in a sex-dependent fashion (see

Figure 5). Particularly, female rats pretreated with
2.0 mg/kg methylphenidate had significantly longer paw

lick latencies when compared to male rats in the same
pretreatment condition or female rats pretreated with

5.0 mg/kg methylphenidate (sex x pretreatment interaction,

F (3, 138) = 4.726, p < 0.05, Tukey tests, p < 0.05,

T|2 = 0.064) . Importantly, however,
methylphenidate-pretreated rats did not differ from

saline-pretreated rats.
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Baseline Hot Plate

Pretreatment Drug (mg/kg)

Figure 3. Mean (±SE) Baseline Paw-Lick Latency of Male and

Female Rats (N = 162) Pretreated with Saline, 2.0 mg/kg
Methylphenidate, or 5.0 mg/kg Methylphenidate from PD 11
to PD 20. Data in this Figure are Collapsed Across

Baseline Trials.
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Hot Plate

DAMGO Dose (ng)
Figure 4. Mean (±SE) Paw-Lick Latency of DAMGO (0, 1.0,

3.33, or 10.0 pig i.c.v.) Treated Male and Female Rats
(N = 162) on the Hot Plate Task. Rats were Pretreated with
Saline or Methylphenidate (2.0 or 5.0 mg/kg) from PD 11 to
PD 20 and Tested with DAMGO on PD 60. aSignificantly

Different from Saline-Treated Rats. bSignificantly
Different from Rats Treated with 1.0 |ig DAMGO.
cSignificantly Different from Rats Treated with 3.33 p,g

DAMGO.
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Hot Plate

Pretreatment Drug (mg/kg)

Figure 5. Mean (±SE) Paw-lick Latency of Male and Female
Rats (N = 162) on the Hot Plate Task. Rats were pretreated
with Saline or Methylphenidate (2.0 or 5.0 mg/kg) from PD

11 to PD 20 and Tested with DAMGO. Data in this Figure are
Collapsed Across the Three Doses of DAMGO (1.0, 3.33, or

10.0 |ug i.c.v.). aSignificantly Different from Female Rats
that Received 2.0 Methylphenidate Pretreatment.
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Experiment 2: 050,488 Systemic Injections

Tail-Flick
Similar to the DAMGO experiment, basal responsiveness
on the tail-flick task differed significantly by sex,
because male rats had significantly greater baseline

latencies when compared to female rats (see Figure 6; sex
main effect, F (1, 152) = 3.990, p < 0.05, T|2 - 0.027).

Methylphenidate pretreatment did not alter baseline
responding on the tail-flick task. 050,488 administration
greatly increased tail-flick latencies. Specifically,

animals receiving any of the three doses of 050,488 (5.0,
10.0, or 20.0 mg/kg) showed significantly greater

latencies when compared to rats receiving saline (see

Figure 7). In addition, the highest dose of 050,488
(20.0 mg/kg) produced greater tail-flick latencies when

compared to rats that received the two lower doses (5.0
and 10.0 mg/kg)

[drug main effect, F (3,151) = 26.696,

p < 0.001, Tukey tests < 0.05, T|2 = 0.387). The
responsiveness to 050,488 differed by sex, because male

rats that received 050,488 demonstrated significantly
greater tail-flick latencies than female rats given
050,488

(see Figure 8; sex x 050,488 interaction,

F (3,151) = 4.803, p < 0.05, Tukey tests, p < 0.05,

63

r|2 = 0.102). In addition, a sex x methylphenidate x
U50-488 interaction was detected. Specifically, male rats
that received 5.0 mg/kg methylphenidate pretreatment

demonstrated greater responsiveness to 10.0 mg/kg U50,488

when compared to saline-pretreated controls (see upper

panel, Figure 9; sex x methylphenidate x U50,488
interaction, F (6,151) - 2.304, p < 0.05, Tukey tests,
p < 0.05, r|2 = 0.098) . Interestingly, females rats that

received 5.0 mg/kg methylphenidate pretreatment in the
U50,488 control condition (i.e., animals that received

0 mg/kg U50,488 prior to tail-flick testing) demonstrated
significantly shorter latencies when compared to saline

pre-treated female controls [see lower panel, Figure 9;
Tukey tests, p < 0.05].
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Baseline Tail Flick

Pretreatment Drug (mg/kg)

Figure 6. Mean (+SE) Baseline Tail-flick Latency of Male
and Female Rats (N = 151) Pretreated with Saline,

2.0 mg/kg Methylphenidate, or 5.0 Methylphenidate from

PD 11 to PD 20. Data in this Figure are Collapsed Across
Baseline Trials. aSignificantly Different from Male Rats.
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Tail Flick

U50-488H Dose (mg/kg)

Figure 7. Mean (+SE) Tail-Flick Latency of U50,488

(0, 5.0, 10.0, or 20.0 mg/kg s.c.) Treated Rats (N = 151).
Rats were Pretreated with Saline or Methylphenidate (2.0
or 5.0 mg/kg) from PD 11 to PD 20 and Tested with U50,488

on PD 60. aSignificantly Different from Saline-Treated

Rats. bSignificantly Different from Rats Treated with
5.0 mg/kg U50,488. cSignificantly Different from Rats

Treated with 10.0 mg/kg U50,488.
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Tail Flick

Figure 8. Mean (±SE) Tail-Flick Latency of U50,488
(0, 5.0, 10.0, or 20.0 mg/kg s.c.) Treated Male and Female
Rats (N = 151). Rats were Pretreated with Saline or

Methylphenidate (2.0 or 5.0 mg/kg) from PD 11 to PD 20 and
Tested with U50,488 on PD 60. aSignificantly Different
from Saline-Treated Rats. bSignificantly Different from

Female Rats Treated with 5.0 mg/kg U50,488. cSignificantly

Different from Female Rats Treated with 10.0 mg/kg
U50, 488.
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U50-488H Dose (mg/kg)

Mean (±SE) Tail-Flick Latency of Male and Female
Rats (N = 151) Receiving 050,488 (0, 5.0, 10.0, or

20.0 mg/kg s.c.). Rats were Pretreated with Saline or
Methylphenidate (2.0 or 5.0 mg/kg) from PD 11 to PD 20 and
Injected with U50,488 on PD 60. aSignificantly Different

from Rats that Received Saline from PD 11 to PD 20.
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Hot Plate

Basal responding on the hot plate task did not differ
by sex or methylphenidate pretreatment (see Figure 10).

Similar to the response on the tail-flick task, rats
receiving U50,488 exhibited significantly greater

latencies when compared to rats receiving saline (see
Figure 11). In particular, rats receiving 10.0 and

20.0 mg/kg U50,488 demonstrated greater latencies than

rats receiving saline, with animals receiving 20.0 mg/kg
U50,488 having the greatest latency (F 3,152) = 27.620,
p < 0.001, Tukey tests, p < 0.05, r]2 = 0.393). Male rats
that received U50,488 exhibited greater latencies than

female rats that received U50,488 (see Figure 12; sex main
effect, F (1,152) = 7.674, p < 0.05, T]2 = 0.057).
Methylphenidate pretreatment did not alter the
responsiveness to U50,488 on the hot plate task.
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Baseline Hot Plate

Pretreatment Drug (mg/kg)
Figure 10. Mean (±SE) Baseline Hot Plate Latency of Male
and Female Rats (N = 152) Pretreated with Saline,
2.0 mg/kg Methylphenidate, or 5.0 Methylphenidate from PD

11 to PD 20. Data in this Figure are Collapsed Across

Baseline Trials.
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10.0, or 20.0 mg/kg s.c.) Treated Male and Female Rats

(N - 152) on the Hot Plate Task. Rats were Pretreated with

Saline or Methylphenidate (2.0 or 5.0 mg/kg) from PD 11 to
PD 20 and Tested with DAMGO on PD 60. aSignificantly
Different from Saline-Treated Rats. bSignificantly

Different from Rats Treated with 5.0 mg/kg U50,488.
cSignificantly Different from Rats Treated with 10.0 mg/kg

U50,488.
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Hot Plate

Figure 12. Mean (±SE) Paw-Lick Latency of 050,488 (0, 5.0,

10.0, or 20.0 mg/kg, s.c.) Treated Male and Female Rats
(N = 152) on the Hot Plate Task. Rats were Pretreated with

Saline or Methylphenidate (2.0 or 5.0 mg/kg) from PD 11 to

PD 20 and Tested with 050,488 on PD 60. aSignificantly
Different from Saline-Treated Rats. bSignificantly
Different from Rats Treated with 5.0 mg/kg 050,488.
cSignificantly Different from Rats Treated with 10 mg/kg

050,488.
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CHAPTER TWELVE
DISCUSSION

Methylphenidate pretreatment enhances morphineinduced antinociception (Halladay et al., 2009). Because
morphine activates MOR, KOR, and DOR (Yamado et al.,

2006), it is uncertain which receptor(s) are responsible
for this methylphenidate effect. Therefore, the goal of
the present study was to determine if early exposure to

methylphenidate alters the function of MOR and KOR. Two

specific hypotheses were made:

(1) animals pretreated with

methylphenidate would show enhanced responsiveness to

DAMGO (a MOR selective agonist) and (2) animals pretreated
with methylphenidate would show enhanced responsiveness to

U50,488 (a KOR selective agonist).
The prediction that DAMGO-mediated antinociception

would be enhanced by methylphenidate pretreatment was not
supported by the data. Specifically, there were no

significant differences between methylphenidate-

pretreated rats and saline-pretreated rats in their
responsiveness to DAMGO. However, there was a sex by

methylphenidate interaction, because DAMGO-treated female

rats receiving 2.0 mg/kg methylphenidate pretreatment had
greater latencies on the hot plate task than male rats
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that received the identical methylphenidate pretreatment
or female rats that received 5.0 mg/kg methylphenidate

pretreatment.
The prediction that early methylphenidate

pretreatment would enhance U50,488-mediated
antinociception was supported. Male rats that received
5.0 mg/kg methylphenidate pretreatment demonstrated

significantly greater tail-flick latencies after
administration of 10.0 mg/kg U50,488 when compared to
saline-pretreated male rats. Curiously, female rats that
received 5.0 mg/kg methylphenidate pretreatment in the

U50,488 control condition (i.e., rats that received
0 mg/kg U50,488 prior to testing) exhibited significantly

shorter latencies on the tail-flick task when compared to
saline-pretreated female rats. The results of the present
experiment suggest that early exposure to methylphenidate
increases the -sensitivity of KOR in male rats and enhances

responsiveness to nociceptive stimuli in female rats.

In general, the literature on sex differences in
basal responsiveness to nociceptive stimuli are

inconsistent, with some reports showing greater basal
sensitivity in males, others showing greater basal
sensitivity in females, and others showing no sex

differences (for a review, see Mogil, Chesler, Wilson,
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Juraska, & Stenberg, 2000). In the present study, male

rats in both experiments showed significantly greater
baseline latencies in the tail-flick task when compared to

female rats. The gender difference in baseline latencies
was not a consequence of methylphenidate exposure, because

male rats showed greater latencies on the tail-flick task
regardless of pretreatment condition.
Similar to previous findings, the administration of
DAMGO elicited significantly greater latencies on the

tail-flick and hot plate tasks when compared to control
animals (Suh & Tseng, 1990; Vivian & Miczek, 1998). In the

tail-flick task, the highest dose of DAMGO (10.0>|Lig)
yielded the greatest latencies, with no difference between
the low and moderate dose. DAMGO produced a dose-dependent

increase in antinociception on the hot plate task.
Early exposure to methylphenidate did not alter
responsiveness to DAMGO in adulthood. It has previously

been shown that early methylphenidate pretreatment

increases morphine-induced antinociception (Cyr & Morgan,
2009; Halladay et al., 2009). Although it was expected
that methylphenidate pretreatment would enhance

DAMGO-mediated antinociception, the different pattern of
results produced by DAMGO and morphine may be due to drug

pharmacodynamics. DAMGO has different effects at the MOR
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when compared to morphine. For example, DAMGO, unlike
morphine, causes rapid MOR internalization, an

intracellular process that leads to the recycling or
enzymatic inactivation of desensitized receptors (Bailey

et al., 2003; Xu et al., 2007). This difference in

internalization is believed to be a function of the higher
binding affinity that DAMGO displays for MOR when compared

to morphine (McPherson et al., 2010). In addition to being
a MOR agonist, morphine also activates KOR and DOR, and is

capable of inducing antinociception in MOR knockout mice
(Yamado et al., 2006). DAMGO, on the other hand, seems to
be completely mediated by MOR because CTOP, a selective

MOR antagonist, eliminates DAMGO-induced antinociception
(Watanabe et al., 2006). Therefore, the increased
responsiveness to morphine observed after early

methylphenidate pretreatment does not appear to be
mediated strictly by alterations in MOR.
Although there was no significant main effect of

methylphenidate on DAMGO-mediated antinociception, there
were significant sex differences within methylphenidate-

pretreatment groups. Methylphenidate (2.0 mg/kg)
pretreated female rats given DAMGO demonstrated

significantly greater latencies on the hot plate task when
compared to identically treated male rats and female rats
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that received 5.0 mg/kg methylphenidate pretreatment. This

finding is surprising, because most investigations show
that male rats are more sensitive to DAMGO-mediated

antinociception than female rats (Kest et al., 2000).
Other studies have shown no differences in DAMGO-mediated

antinociception in the tail-flick (Islam, Cooper, &

Bodnar, 1993) or hot plate tasks (Bartok & Craft, 1997).

However, because methylphenidate-pretreated rats did not

significantly differ from saline-pretreated controls, and
the effect size was small (t|2 = 0.064), this finding is

likely not replicable.
Methylphenidate has occasionally been reported to

induce sex-dependent behavioral effects in male and female
rats. For example, methylphenidate treatment from PD 11 to

PD 20 increased break-points for cocaine

self-administration on a progressive ratio schedule in
young adult male rats, but not young adult female rats

(Crawford et al., 2010). Using the same pretreatment
regimen, methylphenidate-pretreated male rats demonstrated

more robust morphine-induced locomotor activity in
adulthood when compared to methylphenidate-pretreated

female rats (Halladay et al., 2009). In other studies,
methylphenidate-pretreated females demonstrated a more
enhanced effect when compared to males. Using the
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conditioned place preference procedure, the preference for
a cocaine-paired environment was enhanced in female rats
that had been exposed to methylphenidate from PD 20 to PD

35 when compared to saline-pretreated controls (Brenhouse,

Napierata, Kussmaul, Leussis, & Andersen, 2008) .

Conversely, methylphenidate-pretreated males demonstrated
a diminished preference for the cocaine-paired environment
after cocaine challenge (Brenhouse et al., 2008).

The administration of_U50,488 greatly increased

latencies on the tail-flick and hot plate tasks. This

finding is consistent with the literature showing that
U50,488 is an effective antinociceptive compound on both
nociceptive tasks (Jhamandas & Sutak, 1.986; Stoffel,

Ulibarri, Folk, Rice, & Craft, 2005). In general, male

rats were more responsive to U50,488 than females, because
males rats had significantly greater latencies on both the

tail-flick and hot plate tasks after administration of
U50,488 (5.0, 10.0, and 20.0 mg/kg). This finding is

consistent with the hypothesis that male rats are more

sensitive to KOR agonists than female rats (Barret et al.,
2002; Lomas et al., 2007).
Methylphenidate pretreatment did not increase

U50,488-induced latencies on the hot plate task. The hot
plate task is a supraspinally-mediated nociceptive task,
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while the tail-flick is a spinally-mediated nociceptive

task (Le Bars et al., 2001). U50,488 is 1000-fold more
sensitive to intrathecal adminstration of the opioid
antagonist quadazocine when compared to i.c.v.

administration (Paul & Tran, 1994). This finding suggests
that U50,488 is mediated spinally (Paul & Tran, 1994). In

addition, dopamine interacts with spinally located KOR,
because the antinociceptive effects of intrathecal U50,488
is abolished by subcutaneous administration of the

dopamine antagonist sulpiride (Omiya, Goto, Suzuki,
Ishige, & Komatsu/ 1998) . Therefore, early methylphenidate

treatment may sensitize KOR in the spinal cord, but not in
the cerebrum.

Morphine, although historically viewed as a MOR
agonist, binds to other opioid receptors and is capable of

inducing antinociception in MOR-knockout mice (Yamada et

al., 2006). This effect in MOR-knockout mice appears to be

mediated by KOR, because administration of the KOR
antagonist, nor-binaltorphimine, abolished morphine

induced-antinociception (Yamada et al., 2006). In the

present study, male rats previously exposed to
methylphenidate exhibited enhanced responsiveness to
U50,488 when compared to saline-pretreated controls, thus

demonstrating that methylphenidate alters U50,488
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functioning. However, early methylphenidate exposure did
not enhance responsiveness to DAMGO. Thus, the ability of

methylphenidate pretreatment to enhance morphine-induced

reward and antinociception may be mediated by

methylphenidate-induced alterations of KOR.

Methylphenidate-pretreated female rats in the control
condition (i.e., female rats that were administered saline
prior to tail-flick testing) exhibited significantly

shorter latencies compared to saline-pretreated female
rats, suggesting that early methylphenidate pretreatment
enhances responsiveness to nociceptive stimuli. Although
speculative, this result suggests that early exposure to

methylphenidate in female rats may lower the threshold of

pain that is mediated in an opioid-independent manner.
Implications of the Present Thesis
The present study found that early methylphenidate

treatment alters opioid system functioning. Specifically,
we showed that early methylphenidate treatment increased
the antinociceptive effects of the KOR agonist, U50,488,

in male rats and increased basal nociception in female

rats. These results are consistent with other studies
showing that adult and preadolescent exposure to

psychostimulants alters KOR functioning (Cyr & Morgan,
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2009; Halladay et al., 2009; Unterwald et al., 1994; Wiley
et al., 2009). These findings also indicate that the
interaction between dopamine and opioid systems develops

fairly early (i.e., prior to PD 20).
The ability of methylphenidate to. alter KOR

functioning may have important implications for the use of

psychostimulants in human children. The kappa opioid
system, in addition to regulating pain, mediates feeding
and drinking behavior, body temperature, depression, and

stress responsivity (Chen, McClatchy, Geller, Tallarida, &

Adler, 2005; Knoll & Carlezon, 2010; Lee & Clifton, 1992;
Wang, Sun, Tao, Chi, & Liu, 2010). Thus, exposing

preschool-aged boys to methylphenidate may cause

alterations in metabolic processes, and increase

depression and anxiety. This is particularly alarming
because children with ADHD frequently suffer from
depression and anxiety (Waxmonsky, 2003). Therefore,

methylphenidate may increase not only the likelihood of

developing these symptoms, but it could also increase the
severity of depression- and anxiety-related disorders.

The increase in basal nociception in female rats
suggests that early methylphenidate exposure lowers the

threshold of pain. Pain is the most prominent complaint of

people who are seeking medical attention, including those
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being treated for psychiatric disorders (Bras, Dordevic,
Gregurek, & Bullajic, 2010; Fishbin, Cutler, Rosomoff, &
Rosomoff, 1997; Gatchel, Peng, Peters, Fuchs, & Turk,

2007). In addition, pain in conjunction with a mental
disorder convolutes diagnosis and treatment (Bras et al.,
2010). Therefore, it is possible that methylphenidate

treatment in preschool-aged girls may decrease the
tolerance for pain and complicate the treatment of other

disorders.
The results of the present study may also help to

explain why early methylphenidate treatment increases
cocaine self-administration (Crawford et al., 2010). It
has been established that the kappa opioid system is

involved in drug relapse. For example, U50,488 enhances

cocaine conditioned place-preference when administered 60
min before testing and reinstates an already extinguished

cocaine conditioned place-preference (Wee & Koob, 2010).
Thus, early exposure to methylphenidate may increase

cocaine self-administration by sensitizing KOR, leading to
more active drug seeking. This leads to an additional
concern of treating young children with methylphenidate,
because this evidence suggests that early exposure to
methylphenidate may increase the susceptibility to drug
dependence in adulthood.
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In summary, while methylphenidate is an efficacious
treatment for ADHD, the present study suggests that there
are potentially serious long-term consequences that can

result from chronic exposure to methylphenidate during
early development. In particular, our findings suggest

that methylphenidate treatment during the preschool years

may increase susceptibility to affective and substance

abuse disorders.
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